-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In a new study, researchers from research institutions such as the National Institute on Aging (NIA) found that existing and emerging cancer drugs may be Therapies for the population to conduct clinical trials
These authors found changes in brain proteins associated with APOE4 genetic risk variants in young post-mortem study participants (average age of death was 39), and correlated these changes with Alzheimer’s disease patients and non-Alzheimer’s disease The changes in the autopsy brain of patients (average age at death of 89 years) were compared
This analysis includes brain samples from the Baltimore Longitudinal Study of Aging, the Religious Orders Study, and other NIA-funded research
Their results showed that an experimental drug for the treatment of liver cancer and Dasatinib, which is approved for chronic myelogenous leukemia, act on some of the proteins related to Alzheimer’s disease, indicating that they may be Potential drugs for the treatment of Alzheimer's disease
Identify early AD proteome characteristics
Picture from Science Advances, 2021, doi:10.
These findings provide evidence for another recent study, demonstrating the value of this data-driven approach in drug reuse research
Note: The original text has been deleted
Reference materials:
Jackson A.